Information about Dolutegravir
Generic Name : DolutegravirUp-to-date prescription details regarding Dolutegravir are provided here.
Understand it's uses, recommended dosages, its indications, how to take, when to take, when not to take, side effects, special precautions, warnings and its and its storage instructions.You will also find a list of the medication's International and Indian brand or trade names, as well as its pricing information. For verification of the information presented on this page or for additional clarifications, it's advisable to consult your doctor.
Trade Names/Brand Names of Dolutegravir
International :
Tivicay
Other Name(s) of Dolutegravir
DTGWhy is Dolutegravir Prescribed? (Indications)
This medication is an integrase inhibitor prescribed for the treatment of HIV-1 infection in adults and pediatric patients aged 12 years and older and weighing at least 40 kg. Dolutegravir works by blocking integrase, an HIV enzyme that prevents the replication and lowers the amount of HIV in the blood.When should Dolutegravir not be taken? (Contraindications)
Coadministration of dolutegravir with dofetilide is contraindicated due to the potential for increased dofetilide plasma concentrations and the risk for serious and/or life-threatening events; hypersensitivity.What is the dosage of Dolutegravir?
For treatment-naïve adults as well as treatment-experienced adults who are INSTI (integrase strand transfer inhibitor) - naïve: 50 mg tablet taken once daily.For treatment-experienced adults who are INSTI-experienced with certain INSTI-associated resistance substitutions or clinically suspected INSTI resistance: 50 mg tablet taken twice daily.
For children aged 12 years and older and weighing at least 40 kg who are treatment-naïve or treatment-experienced INSTI-naïve: 50 mg tablet taken once daily.
How should Dolutegravir be taken?
It comes as a tablet to be taken by mouth with or without food.What are the warnings and precautions for Dolutegravir?
• Caution should be exercised in patients with history of hepatitis B and C, moderate or severe liver impairment, excess fat, pregnancy and children.• Monitor liver enzymes regularly.
• Tivicay should not be used in patients who have experienced a previous hypersensitivity reaction to TIVICAY.
• Appropriate laboratory testing prior to initiating therapy and monitoring for hepatotoxicity during therapy with TIVICAY are recommended.